Ftse Mib
34.490,71
0,00%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.512,78
0,00%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pardes Biosciences Inc (PRDS) Pardes Biosciences Inc (PRDS) Notizie

PRDS

Pardes Biosciences (PRDS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRDS
DataOraFonteTitoloSimboloCompagnia
11/09/202314:00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PRDSPardes Biosciences Inc
31/08/202323:17Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202320:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
31/08/202315:06Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PRDSPardes Biosciences Inc
31/08/202315:03Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202314:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
31/08/202314:53Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314:34Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314:30Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314:15GlobeNewswire Inc.Pardes Biosciences Announces Closing of Tender OfferNASDAQ:PRDSPardes Biosciences Inc
28/08/202317:33Business WireMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesNASDAQ:PRDSPardes Biosciences Inc
17/08/202323:43Business WireMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesNASDAQ:PRDSPardes Biosciences Inc
04/08/202322:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
28/07/202323:08Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:PRDSPardes Biosciences Inc
28/07/202323:04Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:PRDSPardes Biosciences Inc
28/07/202323:01Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:PRDSPardes Biosciences Inc
17/07/202313:58Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:PRDSPardes Biosciences Inc
17/07/202313:11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:PRDSPardes Biosciences Inc
17/07/202313:00GlobeNewswire Inc.Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsNASDAQ:PRDSPardes Biosciences Inc
05/06/202322:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRDSPardes Biosciences Inc
02/06/202322:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRDSPardes Biosciences Inc
05/05/202322:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRDSPardes Biosciences Inc
05/05/202322:01GlobeNewswire Inc.Pardes Biosciences Reports First Quarter 2023 Financial ResultsNASDAQ:PRDSPardes Biosciences Inc
21/04/202322:28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRDSPardes Biosciences Inc
20/04/202313:54Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PRDSPardes Biosciences Inc
20/04/202313:50Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PRDSPardes Biosciences Inc
03/04/202314:00GlobeNewswire Inc.Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19NASDAQ:PRDSPardes Biosciences Inc
14/03/202321:07Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PRDSPardes Biosciences Inc
14/03/202321:01GlobeNewswire Inc.Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:PRDSPardes Biosciences Inc
14/02/202323:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PRDSPardes Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRDS

La tua Cronologia

COIN
SGBTC
ASX
BMGN
Brazilian Metals
BIT
3LPO
Graniteshares 3x Long Sp...
HUOB
MEMEUSDT
Memecoin
COIN
GOLDTKETH
GOLDEN TOKEN
USOTC
WKRCF
Wacker Neuson SE Namen Akt (PK)
BIT
I06774
Intesa Sanpaolo
LSE
0R0P
Blackberry
EU
FRTEN
CAC Telecommunications N...
BIT
F17051
Vontobel Financial Produ...
KOSPI
417310
Koramco The One Reit
AMEX
NHWK
Nighthawk Biosciences
EU
F597S
F597S
USOTC
CAGU
The Castle (CE)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network